Novo and Lilly’s campaigns are not limited to advertisements alone, and both companies are trying to raise awareness around obesity through research studies and conferences.

Megastar Chiranjeevi expressed his gratitude and enthusiasm upon receiving the UK's Lifetime Achievement Award, stating that ...

Spooked by US president's threat, several Indian pharma players lobby for blanket duty waiver on drugs coming from America, ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

Eli Lilly (LLY) stock in focus as the company launches its weight loss therapy Mounjaro in India, beating its rival Novo Nordisk (NVO). Read more here.

The drug, typically taken once a week, would cost between Rs 14,000 and Rs 17,500 per month, depending on the dosage ...

Eli Lilly and Co. has begun selling its blockbuster weight-loss and diabetes drug Mounjaro in India, pipping rivals in a ...

Eli Lilly introduced Mounjaro, a diabetes and weight-loss drug, in India, aiming to tackle obesity and diabetes. With a ...

Eli Lilly has launched its diabetes and weight-loss drug, Mounjaro, in India, outpacing competitor Novo Nordisk. With ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Global pharmaceutical company Eli Lilly and Company (India) has introduced Mounjaro (tirzepatide) in India, a breakthrough drug for the treatment of Type 2 diabetes and obesity. Approved by the ...